Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Colorcon
Merck
Baxter
McKesson
McKinsey
Moodys

Last Updated: May 19, 2022

ZERVIATE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

When do Zerviate patents expire, and what generic alternatives are available?

Zerviate is a drug marketed by Eyevance and is included in one NDA. There are four patents protecting this drug.

This drug has twenty patent family members in five countries.

The generic ingredient in ZERVIATE is cetirizine hydrochloride. There are thirty-nine drug master file entries for this compound. One hundred and thirty-five suppliers are listed for this compound. Additional details are available on the cetirizine hydrochloride profile page.

US Patents and Regulatory Information for ZERVIATE

ZERVIATE is protected by four US patents.

Patents protecting ZERVIATE

Ophthalmic formulations of cetirizine and methods of use
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Ophthalmic formulations of cetirizine and methods of use
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Ophthalmic formulations of cetirizine and methods of use
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Ophthalmic formulations of cetirizine and methods of use
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF OCULAR ITCHING ASSOCIATED WITH ALLERGIC CONJUNCTIVITIS

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eyevance ZERVIATE cetirizine hydrochloride SOLUTION/DROPS;OPHTHALMIC 208694-001 May 30, 2017 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Eyevance ZERVIATE cetirizine hydrochloride SOLUTION/DROPS;OPHTHALMIC 208694-001 May 30, 2017 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Eyevance ZERVIATE cetirizine hydrochloride SOLUTION/DROPS;OPHTHALMIC 208694-001 May 30, 2017 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Eyevance ZERVIATE cetirizine hydrochloride SOLUTION/DROPS;OPHTHALMIC 208694-001 May 30, 2017 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for ZERVIATE

See the table below for patents covering ZERVIATE around the world.

Country Patent Number Title Estimated Expiration
Japan 2021138760 セチリジンの眼科用製剤および使用方法 (OPHTHALMOLOGIC PREPARATION OF CETIRIZINE AND METHODS OF USE) See Plans and Pricing
Japan 2018141022 セチリジンの眼科用製剤および使用方法 (OPHTHALMOLOGIC PREPARATION OF CETIRIZINE AND METHODS OF USE) See Plans and Pricing
European Patent Office 2408453 FORMULATIONS OPHTALMIQUES DE CÉTIRIZINE ET PROCÉDÉS D'UTILISATION (OPHTHALMIC FORMULATIONS OF CETIRIZINE AND METHODS OF USE) See Plans and Pricing
World Intellectual Property Organization (WIPO) 2011116020 See Plans and Pricing
Japan 6893573 See Plans and Pricing
Japan 6033677 See Plans and Pricing
Japan 2012520882 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for ZERVIATE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0663828 C300085 Netherlands See Plans and Pricing PRODUCT NAME: LEVOCETIRIZINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER LEVOCETIRINE DIHYDROCHLORIDE; NAT. REGISTRATION NO/DATE: RVG 26770 20011009; FIRST REGISTRATION: DE 49903.00.00 AND 49904.00.00 20010103
0058146 2001C/045 Belgium See Plans and Pricing PRODUCT NAME: DICHLORHYDRATE DE LEVOCETIRIZINE; NAT RER. NO/DATE: 194 IS 90 F3 20011022; FIRST REG.: DE 49903.00.00 20010103
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Dow
AstraZeneca
Harvard Business School
Boehringer Ingelheim
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.